Global Orphan Drugs Market: Industry Analysis & Outlook (2018-2022)

  • ID: 4594259
  • Report
  • Region: Global
  • 79 Pages
  • Koncept Analytics
1 of 5
Development of Drug Therapies to Skyrocket the Orphan Drugs Market

FEATURED COMPANIES

  • Bristol-Myers Squibb
  • Celgene Corporation
  • Novartis International AG
  • Roche Holding AG
  • MORE

Orphan diseases are typically life-threatening or chronically debilitating for which no or inadequate alternative treatments are available. An orphan disease refers to any rare disease which affects a smaller share of population. Most of the rare diseases are genetic and therefore chronic. Presently, there are around 7000 rare diseases affecting approximately 5-6% of the global population. Half of the population of orphan disease patients is children as most of the genetic orphan diseases occur at birth or childhood.

Generally, orphan diseases are considered to be severe, progressive, degenerative, life-threatening or chronically debilitating diseases which can be caused genetically, infectiously or toxically. Despite knowing the causes of orphan diseases, most of these diseases are still non-curable or lack satisfactory treatments. Majority of the genetic orphan diseases are caused by defects in a single gene due to multiple mutations.

Orphan drug market is likely to witness a growth in future with increasing development and approvals of ultra-rare drugs and rising developments in drugs for rare blood disease. The US and Europe are the major contributors to the global orphan drugs market supported by increased numbers of orphan drug designations. Asia is likely to experience further growth with increasing orphan designations in Japan and improving healthcare facilities.

The global orphan drugs market is expected to grow in future due to prolonged orphan drug market exclusivity, increasing sales of prescription drugs, attractive orphan drug policies, rising healthcare expenditure, improving economies and increasing prevalence of chronic diseases. Key trends & development of this market include rise in orphan drug approvals, accelerating pipeline sales of orphan drugs, development of drug therapies and rising scope in gene therapy. However, there are some factors which can hinder growth of the market including high costs of drugs, increased competition from generic industry, insufficient disease information & research participants and deficiency of diagnostic systems and trained professionals.

The report “Global Orphan Drugs Market: Industry Analysis & Outlook (2018-2022)” provides an extensive research and detailed analysis of the present market along with future outlook. The report discusses the major growth drivers and challenges of the market, covering the US, Europe and Asia along with the global market. The report profiles key players of the market including Roche holding AF, Novartis International AG, Bristol-Myers Squibb and Celgene Corporation.

READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Bristol-Myers Squibb
  • Celgene Corporation
  • Novartis International AG
  • Roche Holding AG
  • MORE

1. Overview
1.1 Orphan Disease
1.2 Orphan Drugs

2. Global Orphan Drugs Market
2.1 Global Orphan Drugs Market by Value
2.2 Global Orphan Drugs Market Forecast by Value
2.3 Global Orphan Drugs Market by Product
2.3.1 Global Revlimid Drug Revenue Forecast
2.3.2 Global Rituxan Drug Revenue Forecast
2.3.3 Global Opvido Drug Revenue Forecast
2.4 Global Orphan Drugs Market by Therapy
2.4.1 Global Oncology Therapy Market Forecast by Value
2.4.2 Global Blood Therapy Market Forecast by Value
2.4.3 Global Central Nervous System Therapy Market Forecast by Value

3. Regional Market Analysis
3.1 The Americas
3.1.1 The US Orphan Drugs Spending Forecast
3.1.2 The US Orphan Drug by Designation Volume
3.1.3 The US Orphan Drug Average & Median Cost per Patient
3.1.4 The US Orphan Drug Average & Median Cost per Patient Forecast
3.1.5 Canada Orphan Drugs Spending
3.1.6 Canada Orphan Drugs Spending Forecast
3.2 Europe
3.2.1 Europe Orphan Drugs Market Forecast by Value
3.2.2 Europe Orphan Drugs Market by Product
3.2.3 Europe Orphan Drug by Designation Volume
3.3 Asia
3.3.1 Japan Orphan Drug by Designation Volume
3.3.2 India Orphan Drugs Market Forecast by Value

4. Market Dynamics
4.1 Growth Drivers
4.1.1 Prolonged Orphan Drug Market Exclusivity
4.1.2 Increasing Sales of Prescription Drugs
4.1.3 Attractive Orphan Drug Policies
4.1.4 Rising Healthcare Expenditure
4.1.5 Improving Economic Condition
4.1.6 Increasing Prevalence of Chronic Diseases
4.2 Key Trends & Development
4.2.1 Rise in Orphan Drug Approvals
4.2.2 Accelerating Pipeline Sales of Orphan Drugs
4.2.3 Development of Drug Therapies
4.2.4 Increasing Scope of Gene Therapy
4.3 Challenges
4.3.1 High Costs
4.3.2 Lack of Diagnostic Systems and Trained Professionals
4.3.3 Insufficient Disease Information and Research Participants
4.3.4 Rising Competition from Generic Industry

5. Competitive Landscape
5.1 Global Market
5.1.1 Revenue and Market Cap Comparison
5.1.2 Global Orphan Drugs Market Share by Company
5.1.3 Global Oncology Orphan Drugs Market Share by Company
5.2 The US
5.2.1 The US Top 10 Orphan Drugs Sales by Company
5.3 Europe
5.3.1 Europe Orphan Drugs Market Share by Company

6. Company Profiles
6.1 Novartis International AG
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategies
6.2 Roche Holding AG
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategies
6.3 Bristol-Myers Squibb
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategies
6.4 Celgene Corporation
6.4.1 Business Overview
6.4.2 Financial Overview
6.4.3 Business Strategies

List of Charts
Types of Orphan Drugs
Orphan Drug Development
Global Orphan Drugs Market by Value (2013-2017)
Global Orphan Drugs Market Forecast by Value (2018-2022)
Global Orphan Drugs Market by Product (2017)
Global Revlimid Drug Revenue Forecast (2017-2022)
Global Rituxan Drug Revenue Forecast (2017-2022)
Global Opvido Drug Revenue Forecast (2017-2022)
Global Orphan Drugs Market by Therapy (2017)
Global Oncology Therapy Market Forecast by Value (2017-2022)
Global Blood Therapy Market Forecast by Value (2017-2022)
Global Central Nervous System Therapy Market Forecast by Value (2017-2022)
The US Orphan Drugs Spending Forecast (2017-2022)
The US Orphan Drug by Designation Volume (2013-2017)
The US Orphan Drug Average & Median Cost per Patient (2013-2017)
The US Orphan Drug Average & Median Cost per Patient Forecast (2018-2022)
Canada Orphan Drugs Spending (2013-2017)
Canada Orphan Drugs Spending Forecast (2018-2022)
Europe Orphan Drugs Market Forecast by Value (2017-2022)
Europe Orphan Drugs Market by Product (2017)
Europe Orphan Drug by Designation Volume (2013-2017)
Japan Orphan Drug by Designation Volume (2013-2017)
India Orphan Drugs Market Forecast by Value (2017-2022)
Global Prescription Drugs Sales (2013-2022)
Global Healthcare Expenditure (2013-2017)
Global GDP Per Capita (2013-2017)
Global Cancer Prevalence (2012-2030E)
The US FDA Orphan Drug Approvals (2010-2017)
The US Orphan Novel Drug Approvals (2010-2017)
Global Worldwide Orphan Drug Pipeline Sales (2018-2024)
Projection of Top 10 Orphan Drugs in Development (phase III/filed) by NPV* (2018)
Global Orphan Drugs Market Share by Company (2017/2024)
Global Oncology Orphan Drugs Market Share by Company (2017/2024)
Europe Orphan Drugs Market Share by Company (2017)
Novartis Sales by Segment (2017)
Novartis Net Sales and Net Income (2013-2017)
Roche Sales by Segments (2017)
Roche Sales and Net Income (2013-2017)
Bristol-Myers Squibb Revenue by Region (2017)
Bristol-Myers Squibb Total Revenue and Net Earnings (2013-2017)
Bristol-Myers Squibb R&D Expenditure (2015-2017)
Celgene Revenue by Region (2017)
Celgene Total Revenue and Net Income (2013-2017)

List of Tables
Orphan Disease Prevalence in Different Nations
Orphan Drug Market Exclusivity
Orphan Drug Policies
Prices and Prevalence of Some Orphan Drugs in the US (2017)
Key Players - Revenue & Market Cap Comparison (2017)
The US Top 10 Orphan Drugs Sales by Company (2017)
Novartis Agreements (2018)
Novartis Major Product Approvals (2018)
Roche Agreements (2017/2018)
Roche Product Approvals (2018)
Bristol-Myers Squibb Agreements (2018)
Celgene R&D Expenditure (2015-2017)

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Novartis International AG
  • Roche Holding AG
  • Bristol-Myers Squibb
  • Celgene Corporation
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll